CLINICAL EVIDENCE
Deliver lasting outcomes.
–10.4 mmHg
Reduction in office systolic BP from baseline at 2 months in combined results from RADIANCE RCTs1
3 years
RADIANCE-HTN SOLO:
Office SBP reduction -17.7 mmHg at 36 months2
RADIANCE-HTN TRIO:
Office SBP reduction -17.3 mmHg3 at 36 months4
8 years
1. Kirtane et al. JAMA Cardiol. 2023;8(5):464-473 2. Rader et al. EuroIntervention 2022;18:e677-e685. 3. In patient population with baseline office SBP ≥ 150 mmHG 4. Bloch et al. Hypertens Res. 2024. Baseline measurement occurred following 4-week standardization on a 3-drug single-pill 5. Zeijen VJM Clini Res Cardiol. 2024. p-value 0.001 for all other changes compared to baseline. Linear mixed-effect models adjusted for medications. Potential procedure-rated AEs including pain, vascular access site complications, and vasospasm are most common. Individual results may vary. See full Important Safety Information here.
ABOUT RECOR
We’re changing the game in chronic care therapies.
At Recor, our purpose is clear: to help people realize a future not bound by chronic disease.
Actual patient not pictured